gptkbp:instance_of
|
gptkb:disease
|
gptkbp:caused_by
|
gptkb:rubella_virus
|
gptkbp:character_traits
|
single serotype
|
gptkbp:clinical_trial
|
mild illness in children
more severe in adults
|
gptkbp:common_name
|
gptkb:German_measles
|
gptkbp:complications
|
gptkb:congenital_rubella_syndrome
|
gptkbp:condition
|
gptkb:multiple_sclerosis
deafness
cataracts
cardiac defects
thrombocytopenic purpura
|
gptkbp:contraindication
|
pregnant women
immunocompromised individuals
|
gptkbp:diagnosis
|
serological testing
|
gptkbp:diseases
|
vaccination campaigns
common in unvaccinated populations
|
gptkbp:epidemiology
|
declined due to vaccination
|
gptkbp:global_eradication_goal
|
gptkb:2020_target_by_WHO
|
gptkbp:history
|
first described in 1752
|
https://www.w3.org/2000/01/rdf-schema#label
|
rubella
|
gptkbp:immunity_duration
|
lifetime after infection
|
gptkbp:incubation_period
|
2 to 3 weeks
|
gptkbp:is_recognized_as
|
gptkb:Physician
|
gptkbp:is_vulnerable_to
|
gptkb:MMR_vaccine
rash
refrigerated
live attenuated vaccine
mild fever
rare allergic reactions
95% or higher
reduced incidence of disease
arthralgia
administered at 12-15 months
booster at 4-6 years
decreased congenital rubella syndrome cases
introduced in 1969
routine childhood vaccination
|
gptkbp:laboratory_confirmation
|
PCR testing
Ig M antibody detection
|
gptkbp:nutritional_value
|
gptkb:Togaviridae
|
gptkbp:prevalence
|
worldwide
|
gptkbp:prevention
|
vaccination
|
gptkbp:public_awareness
|
important for vaccination
|
gptkbp:public_health_measure
|
immunization programs
|
gptkbp:risk_management
|
pregnant women
|
gptkbp:risk_of_transmission
|
from mother to fetus
|
gptkbp:scientific_classification
|
vaccine-preventable disease
|
gptkbp:screenings
|
before pregnancy
|
gptkbp:symptoms
|
fever
rash
lymphadenopathy
|
gptkbp:transmission
|
airborne droplets
|
gptkbp:treatment
|
supportive care
|
gptkbp:vaccine_administration_route
|
subcutaneous injection
|
gptkbp:virus_genus
|
gptkb:Rubivirus
|
gptkbp:bfsParent
|
gptkb:M-M-R_II
|
gptkbp:bfsLayer
|
5
|